Corticotropin-releasing factor antagonists in affective disorders

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Corticotropin-releasing factor (CRF) integrates stress responses, including endocrine, autonomic, immunologic, and behavioral aspects.
• CRF neuronal hyperactivity is implicated in the pathophysiology of affective disorders.
• CRF antagonists are being investigated for potential therapeutic applications.

Purpose of the Study:

• To explore the potential antidepressant and anxiolytic activity of small molecule CRF antagonists.
• To review the development and efficacy of selective CRF(1) receptor antagonists.
• To discuss the broader therapeutic potential of CRF system modulators.

Main Methods:

• Administration of CRF and CRF antagonists to laboratory animals to observe behavioral and physiological effects.
• In vitro and in vivo studies to assess the efficacy of CRF(1) receptor antagonists.
• Review of existing evidence on CRF system involvement in stress and affective disorders.

Main Results:

• Direct central nervous system (CNS) administration of CRF mimics stress responses in animals.
• CRF antagonists block stress-induced behavioral responses in animal models.
• Selective CRF(1) receptor antagonists demonstrate anxiolytic and antidepressant activity in animal behavioral models.

Conclusions:

• Small molecule CRF antagonists show potential as antidepressant and anxiolytic agents.
• CRF system modulators may be valuable for psychiatric, neurodegenerative, and inflammatory disorders.
• Clinical trials are underway to evaluate CRF(1) receptor antagonists for mood and anxiety disorders.